Cardiovascular Disease

ARTESIA Trial: Apixaban for Subclinical AFib

ARTESIA Trial Summary The ARTESIA trial, which stands for “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” was a landmark study aimed at comparing the efficacy and safety of apixaban versus aspirin in patients with subclinical atrial fibrillation (AF). The … Read More

DAPA-MI Trial: Dapagliflozin in MI

DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More

CASTLE HTx Trial: Ablation in HF and AFib

The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More

ADVENT Trial: Pulse Field Ablation for AFib

The ADVENT trial, published in the New England Journal of Medicine in 2023, was a randomized, single-blind, noninferiority trial designed to compare the safety and efficacy of pulsed field ablation with conventional thermal ablation techniques (radiofrequency or cryoballoon) for the … Read More

Target-HTN trial: Lorundrostat in Hypertension

The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More

OCTOBER Trial: OCT in Complex PCI

The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More

LODESTAR Trial: Statin and CAD

The LODESTAR trial, as featured in JAMA in 2023, was a randomized, multicenter, noninferiority trial focusing on coronary artery disease (CAD) treatment strategies. The objective was to assess whether a treat-to-target strategy for low-density lipoprotein cholesterol (LDL-C) is noninferior to … Read More

HEART-FID Trial: Iron in Heart Failure

The HEART-FID trial, as published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled study designed to determine the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating patients with heart failure with reduced … Read More

FIRE Trial: Complete PCI in MI in Older Patients

The FIRE trial, published in the New England Journal of Medicine in 2023, was a multicenter, randomized controlled trial that aimed to evaluate the benefits of complete revascularization versus culprit-lesion-only percutaneous coronary intervention (PCI) in older patients (≥75 years of … Read More

ECLS-SHOCK Trial: Extracorporeal Life Support in Cardiogenic Shock

The ECLS-SHOCK trial, as reported in the New England Journal of Medicine in 2023, was a multicenter, parallel, randomized controlled trial designed to evaluate the efficacy of extracorporeal life support (ECLS) in patients with acute myocardial infarction (MI) complicated by … Read More